TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: T lymphocyte phenotype and functional response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in CD4+ T Lymphocyte Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Global assessment of tolerability by investigator
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Physical Health of Patient at Enrollment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in Physical Health From Baseline to 3-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare Utilization of Patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lesion numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients receiving reproductive health services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of Metyrosine for Psychosis Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: AED skills retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of tacrolimus in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evidence of Active Myocardial Angiogenesis/Remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of canines retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Health-related quality of life (composite measure)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of the Alpha AMS retinal implant system
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Simpson's Index of Diversity (Alpha Diversity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR24 (Sustained Virologic Response at Week 24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Distance Monocular logMAR Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Numeric Rating of Erythema and Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average total SF-36 Health Survey scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Cocaine-abstinent Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Molecular remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AKI reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peak t-PA Release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Clinically Significant Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Theoretical duration of hospitalization in intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction of LDL-C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective Anxiety Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain after oocyte retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial blood pressure-time integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive Abilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of Normoalbuminuric chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under concentration (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects died at weeks 48
Endpoint domain: Mortality/survival
Primary endpoint: Time to functional recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes of Physical Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deviation From Normal Laboratory Ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital Sign Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least 35% Reduction in Spleen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint inflammation and damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Caries experience DMFTS/dmfts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Numeric Pain Rating Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of meningococcal vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phagocytosis measured by JC-1 assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: 28 Day In-hospital Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Blood-based biomarkers for cardiac involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of late progesterone rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Excyclotorsion of the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number and severity of device related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Solicited Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Daily Positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Daily Negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Daily Pain Coping Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Daily Stress Coping Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in postprandial glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients experiencing myalgias, arthralgias and/or joint stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in experimental pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response and unconfirmed complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness of sun lotion in preventing jellyfish stings
Endpoint domain: Adverse events/effects
Primary endpoint: Intensity of Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of plasma C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hypernatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Value of LVEF Percentage Differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Migraine/Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin test result of lyophilized foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cmax of Lidocaine and Prilocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Lidocaine and Prilocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAMTS-13 Activity Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate Dehydrogenase (LDH) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aerobic capacity/endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neuronal response to food vs. nonfood objects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual Analogue Scale pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Time Within Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Break-up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in clinical assessment score COVID 19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Unsuspected Small Airway Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the Voice Handicap Index-10 (VHI-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage Surface Microhardness Recovery (%SMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of fibromyalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of de novo allosensitisation (donor specific antibodies)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extent and severity of new formed adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to first episode of AF>6 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Auditory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee isokinetic power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of cigarettes consumed daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine radiography ordering proportions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: positive culture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of Acute Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: cure of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe Neurodevelopmental Disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Poor Stroke Outcome at Hospital Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Limitation After Stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical Disability After Stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inspiratory muscular unloading (µv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients achieving HbA1c < 6%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Combined Response Rate During the Induction Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen type 1 cross-linked C-telopeptide (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum type 1 procollagen (N-terminal) P1NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol consumption in the last 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medium Molecule Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medium Molecule Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Adverse Drug Reactions (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum intensity of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-treatment percentage inhibition of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variation in irradiated area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of thorough documentation of BSC delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: changes in function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ten Year Risk of Cardiovascular Disease (CVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Summed Pain Intensity Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal system pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of Pulsewatch System
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Atrial Fibrillation Detected by Smartwatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Detection of Atrial Fibrillation by a Patch Monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual analogue scale (VAS) score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross motor Function Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete ablation of the targeted lesion in the bladder wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTC enumeration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of left ventricular end-systolic volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Number of Severe Ocular Adverse Events Related to the Investigational Product
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Ocular Adverse Events Related to Investigational Product
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Severe Non-ocular Adverse Events Related to the Investigational Product
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Non-ocular Adverse Events Related to the Investigational Product
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total number of supplemental aflibercept injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cervical muscles cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cervical muscle T2 relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pathological GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disease free survival at 1 year post HCT
Endpoint domain: Mortality/survival
Primary endpoint: Health Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality-of-Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite memory standard score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intra-individual correlation coefficient between stroke volume and stroke impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ongoing Pregnancy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: BCC Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Changes in MRI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of additional injections during work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immune response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients withdrawn due to gastrointestinal effects
Endpoint domain: Adverse events/effects
Primary endpoint: Markers of high risk coronary diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Myocardial infarction of the new onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Endometritis Plus Wound Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative cumulative analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum Culture Conversion to Negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Study Participants Who Tolerated ST-246
Endpoint domain: Adverse events/effects
Primary endpoint: Failure of noninvasive respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Decreased Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Able to Complete Full Course of Preoperative Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrophysiological substrate responsible for arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activity count (counts/mn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of activity (sedentarity time, light, moderate in %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Number of Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between lower edge of the placenta and internal os
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Sickness absence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 9-month maximal diameter of the aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9-month volume of the aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daily Steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High risk HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: High grade cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Particular Disease Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes